vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and Origin Bancorp, Inc. (OBK). Click either name above to swap in a different company.
Origin Bancorp, Inc. is the larger business by last-quarter revenue ($104.0M vs $86.8M, roughly 1.2× IOVANCE BIOTHERAPEUTICS, INC.). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 3.9%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
Southern Bancorp is a community development financial institution headquartered in Arkadelphia, Arkansas. It was founded in 1986 as Southern Development Bancorporation, and is often referred to simply as "Southern".
IOVA vs OBK — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $104.0M |
| Net Profit | — | $27.7M |
| Gross Margin | 67.4% | — |
| Operating Margin | -84.7% | — |
| Net Margin | — | 26.6% |
| Revenue YoY | 17.7% | — |
| Net Profit YoY | — | — |
| EPS (diluted) | — | $0.89 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $104.0M | ||
| Q4 25 | $86.8M | $103.4M | ||
| Q3 25 | $67.5M | $109.8M | ||
| Q2 25 | $60.0M | $83.5M | ||
| Q1 25 | $49.3M | $94.1M | ||
| Q4 24 | $73.7M | $78.3M | ||
| Q3 24 | $58.6M | $90.8M | ||
| Q2 24 | $31.1M | $96.4M |
| Q1 26 | — | $27.7M | ||
| Q4 25 | — | $29.5M | ||
| Q3 25 | $-91.3M | $8.6M | ||
| Q2 25 | $-111.7M | $14.6M | ||
| Q1 25 | $-116.2M | $22.4M | ||
| Q4 24 | — | $14.3M | ||
| Q3 24 | $-83.5M | $18.6M | ||
| Q2 24 | $-97.1M | $21.0M |
| Q1 26 | — | — | ||
| Q4 25 | 67.4% | — | ||
| Q3 25 | 43.0% | — | ||
| Q2 25 | 5.5% | — | ||
| Q1 25 | -0.8% | — | ||
| Q4 24 | 68.7% | — | ||
| Q3 24 | 46.2% | — | ||
| Q2 24 | -0.8% | — |
| Q1 26 | — | — | ||
| Q4 25 | -84.7% | 36.2% | ||
| Q3 25 | -140.7% | 10.0% | ||
| Q2 25 | -189.8% | 22.3% | ||
| Q1 25 | -245.8% | 30.4% | ||
| Q4 24 | -117.5% | 23.0% | ||
| Q3 24 | -152.1% | 26.1% | ||
| Q2 24 | -327.6% | 27.7% |
| Q1 26 | — | 26.6% | ||
| Q4 25 | — | 28.5% | ||
| Q3 25 | -135.3% | 7.9% | ||
| Q2 25 | -186.2% | 17.5% | ||
| Q1 25 | -235.5% | 23.8% | ||
| Q4 24 | — | 18.2% | ||
| Q3 24 | -142.7% | 20.5% | ||
| Q2 24 | -312.2% | 21.8% |
| Q1 26 | — | $0.89 | ||
| Q4 25 | — | $0.95 | ||
| Q3 25 | — | $0.27 | ||
| Q2 25 | $-0.33 | $0.47 | ||
| Q1 25 | $-0.36 | $0.71 | ||
| Q4 24 | $-0.24 | $0.45 | ||
| Q3 24 | $-0.28 | $0.60 | ||
| Q2 24 | $-0.34 | $0.67 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $698.6M | $1.3B |
| Total Assets | $913.2M | $10.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $297.0M | $424.2M | ||
| Q3 25 | $300.8M | $626.9M | ||
| Q2 25 | $301.2M | $334.1M | ||
| Q1 25 | $359.7M | $486.2M | ||
| Q4 24 | $323.8M | $470.2M | ||
| Q3 24 | $397.5M | $321.2M | ||
| Q2 24 | $412.5M | $288.1M |
| Q1 26 | — | $1.3B | ||
| Q4 25 | $698.6M | $1.2B | ||
| Q3 25 | $702.3M | $1.2B | ||
| Q2 25 | $698.5M | $1.2B | ||
| Q1 25 | $767.9M | $1.2B | ||
| Q4 24 | $710.4M | $1.1B | ||
| Q3 24 | $773.5M | $1.1B | ||
| Q2 24 | $768.5M | $1.1B |
| Q1 26 | — | $10.2B | ||
| Q4 25 | $913.2M | $9.7B | ||
| Q3 25 | $904.9M | $9.8B | ||
| Q2 25 | $907.4M | $9.7B | ||
| Q1 25 | $966.7M | $9.8B | ||
| Q4 24 | $910.4M | $9.7B | ||
| Q3 24 | $991.1M | $10.0B | ||
| Q2 24 | $964.3M | $9.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | — |
| Free Cash FlowOCF − Capex | $-61.9M | — |
| FCF MarginFCF / Revenue | -71.3% | — |
| Capex IntensityCapex / Revenue | 10.7% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-52.6M | $158.9M | ||
| Q3 25 | $-78.7M | $59.3M | ||
| Q2 25 | $-67.4M | $20.6M | ||
| Q1 25 | $-103.7M | $35.6M | ||
| Q4 24 | $-73.3M | $108.5M | ||
| Q3 24 | $-59.0M | $39.6M | ||
| Q2 24 | $-98.4M | $11.9M |
| Q1 26 | — | — | ||
| Q4 25 | $-61.9M | $151.1M | ||
| Q3 25 | $-89.5M | $56.8M | ||
| Q2 25 | $-74.9M | $19.6M | ||
| Q1 25 | $-109.9M | $34.8M | ||
| Q4 24 | $-77.5M | $86.4M | ||
| Q3 24 | $-61.3M | $32.2M | ||
| Q2 24 | $-98.9M | $6.5M |
| Q1 26 | — | — | ||
| Q4 25 | -71.3% | 146.0% | ||
| Q3 25 | -132.7% | 51.7% | ||
| Q2 25 | -124.9% | 23.5% | ||
| Q1 25 | -222.8% | 37.0% | ||
| Q4 24 | -105.1% | 110.3% | ||
| Q3 24 | -104.6% | 35.5% | ||
| Q2 24 | -317.9% | 6.8% |
| Q1 26 | — | — | ||
| Q4 25 | 10.7% | 7.6% | ||
| Q3 25 | 16.1% | 2.3% | ||
| Q2 25 | 12.4% | 1.2% | ||
| Q1 25 | 12.6% | 0.8% | ||
| Q4 24 | 5.7% | 28.1% | ||
| Q3 24 | 3.9% | 8.1% | ||
| Q2 24 | 1.4% | 5.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | 5.38× | ||
| Q3 25 | — | 6.88× | ||
| Q2 25 | — | 1.41× | ||
| Q1 25 | — | 1.59× | ||
| Q4 24 | — | 7.60× | ||
| Q3 24 | — | 2.13× | ||
| Q2 24 | — | 0.57× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
OBK
| Net Interest Income | $87.2M | 84% |
| Noninterest Income | $16.8M | 16% |
